| Literature DB >> 26036700 |
Rameshwar Patil1, Pallavi R Gangalum1, Shawn Wagner2, Jose Portilla-Arias1, Hui Ding1, Arthur Rekechenetskiy1, Bindu Konda1, Satoshi Inoue1, Keith L Black1, Julia Y Ljubimova1, Eggehard Holler3.
Abstract
Currently, there is no gadolinium-based contrast agent available for conventional magnetic resonance imaging (MRI) detection of amyloidal beta (Aβ) plaques in Alzheimer's disease (AD). Its timely finding would be vital for patient survival and quality of life. Curcumin (CUR), a common Indian spice effectively binds to Aβ plaques which is a hallmark of AD. To address this binding, we have designed a novel nanoimaging agent (NIA) based on nature-derived poly(β-l-malic acid) (PMLA) containing covalently attached gadolinium-DOTA(Gd-DOTA) and nature-derived CUR. The all-in-one agent recognizes and selectively binds to Aβ plaques and is detected by MRI. It efficiently detected Aβ plaques in human and mouse samples by an ex vivo staining. The method can be useful in clinic for safe and noninvasive diagnosis of AD.Entities:
Keywords: Alzheimer disease; curcumin; MRI; nanoimaging agent; polymalic acid
Mesh:
Substances:
Year: 2015 PMID: 26036700 PMCID: PMC4794283 DOI: 10.1002/mabi.201500062
Source DB: PubMed Journal: Macromol Biosci ISSN: 1616-5187 Impact factor: 4.979